| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Lancet Oncology, The | 2018 | 1.1K |
| Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | New England Journal of Medicine | 2018 | 1K |
| Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis | JAMA Oncology | 2018 | 277 |
| Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS | Annals of Oncology | 2018 | 260 |
| Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis | BMJ, The | 2018 | 191 |
| CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials | Annals of Oncology | 2018 | 132 |
| Overview of current systemic management of EGFR-mutant NSCLC | Annals of Oncology | 2018 | 100 |
| Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study | Lancet Respiratory Medicine,the | 2018 | 86 |
| Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study | Future Oncology | 2018 | 75 |
| Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study | The Lancet Gastroenterology and Hepatology | 2018 | 69 |
| Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study | Annals of Oncology | 2018 | 65 |
| Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection | Journal of Hepatology | 2018 | 53 |
| Neuroprotective Role of Phytochemicals | Molecules | 2018 | 53 |
| Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program | Journal of Thoracic Oncology | 2018 | 45 |
| Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy | Seminars in Liver Disease | 2018 | 45 |
| Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials | Clinical Lung Cancer | 2018 | 39 |
| A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing | Cancer Immunology Research | 2018 | 39 |
| Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response | European Journal of Cancer | 2018 | 38 |
| Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan | Journal of Cancer | 2018 | 34 |
| Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS | Analytica Chimica Acta | 2018 | 28 |
| Targeting tumor-infiltrating Ly6G myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma | International Journal of Cancer | 2018 | 28 |
| Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model | Prostate Cancer and Prostatic Diseases | 2018 | 25 |
| Adiposity, Inflammation, and Breast Cancer Pathogenesis in Asian Women | Cancer Prevention Research | 2018 | 24 |
| Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors | Cancer Research | 2018 | 23 |
| Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer | Photodiagnosis and Photodynamic Therapy | 2018 | 20 |
